Clinical Trial Update: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rolapitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Rolapitant (rolapitant)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 3 | Status: COMPLETED | Results posted: 2015-11-04